Anti-osteoporosis agent-8_product_DataBase

Bioactivity	Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC50 is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model[1].
Invitro	Anti-osteoporosis agent-8 (0-10 μM，5 天) 通过激活 BMP2 信号通路促进 MC3T3-E1 细胞中的成骨细胞分化[1].Anti-osteoporosis agent-8 (5 μM，6 h) 通过抑制 MAPK 和 NF-κB 信号通路，抑制破骨细胞相关基因的表达、破骨细胞生成和破骨细胞骨吸收[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Anti-osteoporosis agent-8 相关抗体: Western Blot Analysis[1] Cell Line:
In Vivo	Anti-osteoporosis agent-8 (10 mg/kg，腹腔注射，每 2 天一次，持续 8 周) 可预防 C57BL/6 小鼠模型中卵巢切除引起的骨质流失[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
Formula	C18H19F3N2O2Se
Molar Mass	431.31
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Wu Y, et al., Design, Synthesis, and Biological Evaluation of β-Trifluoroethoxydimethyl Selenides as Potent Antiosteoporosis Agents. J Med Chem. 2024 May 9;67(9):7585-7602.

PeptideDB